Oncogenic mutations of BRAF lead to constitutive ERK activity that supports melanoma cell growth and survival. While Ca 21 signaling is a well-known regulator of tumor progression, the crosstalk between Ca 21 signaling and the Ras-BRAF-MEK-ERK pathway is much less explored. Here we show that in BRAF mutant melanoma cells the abundance of the plasma membrane Ca 21 ATPase isoform 4b (PMCA4b, ATP2B4) is low at baseline but markedly elevated by treatment with the mutant BRAF specific inhibitor vemurafenib. In line with these findings gene expression microarray data also shows decreased PMCA4b expression in cutaneous melanoma when compared to benign nevi. The MEK inhibitor selumetinib-similarly to that of the BRAF-specific inhibitor-also increases PMCA4b levels in both BRAF and NRAS mutant melanoma cells suggesting that the MAPK pathway is involved in the regulation of PMCA4b expression. The increased abundance of PMCA4b in the plasma membrane enhances [Ca 21 ] i clearance from cells after Ca 21 entry. Moreover we show that both vemurafenib treatment and PMCA4b overexpression induce marked inhibition of migration of BRAF mutant melanoma cells. Importantly, reduced migration of PMCA4b expressing BRAF mutant cells is associated with a marked decrease in their metastatic potential in vivo. Taken together, our data reveal an important crosstalk between Ca 21 signaling and the MAPK pathway through the regulation of PMCA4b expression and suggest that PMCA4b is a previously unrecognized metastasis suppressor.
Malignant melanoma is a highly invasive and metastatic type of cancer with poor prognosis. In melanoma BRAF is the most frequently mutated oncogene-present in up to 60% of tumors-that induces the constitutive activation of the RAS-RAF-MEK-ERK signaling cascade. 1, 2 The introduction of vemurafenib-an inhibitor showing considerable selectivity towards the predominant V600E mutant form of BRAFfundamentally changed the therapeutic options for melanoma. 3, 4 Nevertheless, a number of BRAF mutant melanomas show limited response due to intrinsic resistance and initially responding patients often relapse due to acquired resistance. 5, 6 Recent advances in immunotherapy have led to important improvements in clinical outcome. For metastatic melanoma immune checkpoint inhibitors are becoming the standard of care. 7, 8 Programmed death 1 (PD1) receptor and cytotoxic T-lymphocyte 4 (CTL4) targeting antibodies are used alone or in combination with similar response rate (30-40%) among BRAF mutant and non-BRAF mutant patients, although in the majority of BRAF mutant cases the most rapid response is still achieved with the combination of BRAF and MEK inhibitors. 9 Despite these advances, there are nonresponding or relapsing patients in both of these novel treatment regimens. Therefore, further studies are needed to identify additional molecular targets to fight this malignancy more effectively. Cell migration is a prerequisite for invasion that consequently contributes to tumor progression and metastasis. 10 Ca 21 signaling regulates several steps in the migratory process, such as relocation of focal adhesions, rear-end retraction and cytoskeleton redistribution. 11 It has been shown in several types of cancer that specific mutations and/or changes in subcellular localization of certain Ca 21 transporting molecules can significantly alter intracellular Ca 21 signaling. 12, 13 The expression of Ca 21 channels RyR2 and P2X7 was found to be upregulated in BRAF mutant melanoma cells; and P2X7 was shown to have an antiapoptotic effect upon simultaneous stimulation with apoptosis inducer 2ME (2-methoxyestradiol) and P2X7 agonist ATP. Conversely, downregulation of P2X7 expression by siRNA sensitized the cells to 2ME treatment. 14 Increased Ca 21 influx through store operated Ca 21 entry was shown to promote the migratory and metastatic activity of melanoma cells. 15, 16 Furthermore, stromal interaction molecule 1 (STIM1) and Orai calcium release-activated calcium modulator 1 (ORAI1) initiated Ca 21 oscillations that were found to promote invadopodium assembly and extracellular matrix (ECM) degradation in melanoma cells. 17 Silencing of ORAI and STIM proteins decreased migratory and metastatic potential of melanoma cells. [15] [16] [17] Additionally, T-type channel blockers of clinical use (mibefradil and pimozide) reduced the proliferation rate and promoted cell death in a metastatic melanoma cell line. 18 It was also shown that combined treatment with vemurafenib and thapsigargin-an inhibitor of the sarco/endoplasmic reticulum Ca 21 ATPase
(SERCA) and an endoplasmic reticulum (ER) stress inducercould induce apoptosis even in vemurafenib resistant cells. 19 The Ca 21 extrusion proteins in the plasma membrane, the plasma membrane Ca 21 ATPases (PMCAs), are critical regulators of the maintenance of cellular Ca 21 homeostasis and thus regulate vital cellular processes such as cell cycle, apoptosis or migration. 20 These pumps are encoded by four different genes (PMCA1-4), and alternative mRNA splicing results in >20 variants. 21 Changes in PMCA expression during malignant transformation have been described in several tumor types, but not in melanoma so far. Major alterations were identified in the expression and activity of certain PMCA isoforms in colorectal 22, 23 and breast cancer cells. 24, 25 PMCA4 expression was down-regulated in colorectal tumor tissues as compared to normal colon tissue. 26 In this study, we investigated the role of PMCAs in the maintenance of intracellular Ca 21 
Material and Methods

Cell culture
Two BRAF (V600E) mutant (A375, A2058), an NRAS mutant (MJZJ (VM15)) and one BRAF/NRAS wild-type (MEWO) melanoma cell lines were used. MEWO, A375 and A2058 were purchased from ATCC. MJZJ cell line was established at the Institute of Cancer Research at the Medical University of Vienna. 27 All cell lines including the genetically
What's new?
New results may give researcher another way to attack metastatic melanoma. Commonly, melanomas have a mutated copy of BRAF, and current therapies focus on these mutants. In search of new target molecules, these authors looked at the calcium ion signaling system, which promotes cell migration and invasion. They found that BRAF-mutant melanoma cells have less of the plasma membrane calcium ion pump molecule PMCA-4b. Treatment with mutant BRAF inhibitor boosts PMCA-4b and slows the migration of cancer cells. Furthermore, PMCA-4b overexpression reduced metastatic potential of cells in vivo. This study is the first to show that PMCA-4b could hinder metastasis.
modified A375 cells were subjected to STR analysis at the Medical University of Vienna. Cells were cultured in DMEM supplemented with 10% FBS, 100 mg/ml streptomycin, 100 U/ml penicillin at 378C and 5% CO 2 in a humidified atmosphere.
Treatment of melanoma cell lines
The BRAF (V600E) specific inhibitors vemurafenib (PLX4032) and GDC0879, and the MEK kinase inhibitor selumetinib (Selleck Chemicals, Munich, Germany) were dissolved in DMSO and stored at 2808C. 23 Total protein from the cells was precipitated by addition of 6% TCA and was analyzed by Western blot as described previously. 23 The following primary antibodies were used: mouse monoclonal anti-PMCA4b (JA3, recognizing the region between residues 1,156 and 1,180, which is specific to hPMCA4b, 28 dilution 1:1,000), rabbit polyclonal anti-PMCA1 (Affinity BioReagents, PA1-914, dilution 1:1,000), anti-PMCA2 and anti-PMCA3, 29 mouse monoclonal anti-SERCA2 (IID8, dilution 1:2,500, Sigma-Aldrich, S1439), mouse monoclonal anti-SERCA3 (PL/IM430, dilution 1:200) described in Ref. 23 , rabbit monoclonal anti-phospho-p44/ 42MAPK (ERK1/2) (Cell Signaling, CST4370S, dilution 1:1,000), mouse monoclonal anti-ERK1/2 (MK1) (Santa Cruz, sc135900, dilution 1:500), rabbit polyclonal anti-beta-tubulin (Abcam, ab6046), mouse monoclonal anti-BRAF-V600E (VE 1 ) (Spring Bioscience Corp. E19290), chicken polyclonal anti-GFP (AVES, GFP-1020). Subsequently HRP-conjugated anti-rabbit, anti-mouse and anti-chicken secondary antibodies (Jackson ImmunoResearch, dilution 1:10,000) were applied and for detection Pierce ECL Western Blotting Substrate (Thermo Scientific) and luminography were used. Densitometric analysis was done by ImageJ software v1.42q.
Immunofluorescence
Cells were treated with 0.5 mM vemurafenib for 48 to 72 hr. Cells were washed twice with 378C PBS and fixed with 4% paraformaldehyde for 15 min at room temperature. Immunostaining experiments using mouse monoclonal antiPMCA4b antibody JA3, 28 (dilution: 1:200) was performed as described previously. 25 Images were taken by an Olympus IX-81 and a Zeiss LSM500 confocal laser scanning microscopes.
Ca 21 signal measurements
Cells were treated with 0.5 mM vemurafenib for 48/72 hr. Prior to the experiment medium was changed to phenol redfree DMEM containing 10 mM HEPES pH 7.4 and 10% FBS. 21 influx was triggered by the addition of 2 mM A23187. In order to inhibit PMCA activity, 1 mM LaCl 3 was added at the A23187-induced peak Ca 21 . Images were taken by Olympus IX-81 confocal laser scanning microscope with a 603 (1.4) oil immersion objective and Fluoview FV500 software v4.1. Z-resolution was set to 1 mm, images were taken every 0.3 s. The relative fluorescence intensities were calculated as F/F 0 (where F 0 was the average initial fluorescence) and data were analyzed with the Prism4 software v4.01 (GraphPad Software).
Migration assay
Cell migration was quantified by videomicroscopic measurements as described earlier. 30 Briefly, cells were seeded in the inner eight wells of 24-well plates (Corning Incorporated, Corning, NY). Following overnight culture in normal medium, the culture medium was changed to CO 2 -independent medium (Gibco-BRL Life Technologies, Carlsbad, CA) supplemented with FCS and 4 mM glutamine. Cell movement was recorded in a custom designed incubator built around an inverted phase-contrast microscope (World Precision Instruments, Sarasota, FL) at 378C and room ambient atmosphere. Images of three neighboring microscopic fields in each well were taken every 5 min. In case of treatments, after 24 hr of baseline recording, cells were treated with 0.5 mM vemurafenib and images were taken for 72 hr. Migration data were retrieved by a custom made cell-tracking program that enables manual marking of individual cells. Cell motility was quantified as the net displacement of tracked cells between 0 to 12 and 48 to 60 hr of recordings with or without treatment using the 15-min interval images.
Morphological analysis
Image analysis was performed on the videomicroscopic images of A375 cells expressing GFP or GFP-PMCA4b. Computer-based analysis of the morphology of individual cells was performed with ImageJ 1.47v using the Analyze Particle function. Morphological parameters included: cellular area, aspect ratio (defined as (major axis)/(minor axis) of the ellipse which best fits the shape of the cell) and circularity (defined as 4p* (cell area)/(cell perimeter) 2 ).
Generation of cell lines
To establish MEWO-GFP, MEWO-GFP-PMCA4b, A375-GFP, A375-GFP-PMCA4b-I and GFP-PMCA4b-II cell lines, the SB-CAG-GFP-PMCA4b-CAG-Puromycin construct was generated which contains a Sleeping Beauty transposon system. The original SB-CAG-GFP-ABCG2-CAG-Puromycin vector was a generous gift from T. Orban. 31 From this vector, GFP-ABCG2 was excised by the AgeI and BclI enzyme pair. Next, GFP-tagged PMCA4b was cut out from the pEGFPPMCA4b template plasmid 32 in two steps; the vector was opened by a full digestion with ClaI restriction enzyme, then the GFP-PMCA4b was cut out by a partial digest with AgeI and BamHI, and ligated. Stable transfection was performed as described earlier.
25,33 2 to 3.5 3 10 5 MEWO and A375 cells/well were seeded on a six-well plate. Cells were transfected with a mixture of SB-CAG-GFP-PMCA4b-CAGPuromycin transposon construct and SB100x transposase plasmid in a 1:10 ratio using the Fugene HD transfection reagent (Roche Applied Science). Forty-eight hr after transfection, the medium was changed to selection medium containing 1 mg/ml puromycin dihydrocloride. Selection was continued until all non-transfected cells had died.
Cell proliferation
Proliferation was measured by ELISA detection of BrdU incorporation (Roche Applied Science, Vienna, Austria, 11 647 229 001) according to the manufacturer's protocol. A375-GFP, A375-PMCA4bI and II cells were seeded in 96-well plates in triplicates (1 3 10 4 cells/well). Forty-eight hr later cells were labeled with 10 mM BrdU for 2 hr at 378C. Absorbance was measured at 370 nm (reference: 492 nm) and calculated as A 370 2 A 492 .
Quantitative real-time reverse transcription PCR (qPCR)
In order to compare the mRNA level of several Ca 21 channels and EMT markers mRNA was isolated with TRIzol reagent (Life Technologies) from vemurafenib-treated and control A375 and A2058 cells. Reverse transcription was performed with RevertAid Reverse Transcriptase (Thermo Scientific) and amplification was done with the Maxima SYBR Green maser mix (Thermo Scientific) on an Applied BiosystemsV R 7500 Real-Time PCR System. Primer pairs for E-cadherin, ZEB1, snail, vimentin and GAPDH (for normalization) were used as previously described. 34 All other primers used are found in Supporting Information Table 1 . For quantification of PMCA4b transcripts, the TaqMan assays Hs00608066_m1 (PMCA4b) and Hs99999905_m1 (GAPDH, both from Thermo Scientific) were used. 
Results
PMCA4b is upregulated in BRAF mutant melanoma cells after inhibition of the BRAF-MEK-ERK pathway
Vemurafenib (PLX4032) and GDC0879 are low molecular weight inhibitors targeting mutant BRAF. They block MEK and ERK signaling selectively in cells with a BRAF (V600E) mutation. 35 Since the expression of plasma membrane Ca 21 ATPases are often altered in cancer, 22, 23 we tested if treatment of BRAF mutant and wild-type melanoma cells with these BRAF specific inhibitors would affect their expression pattern. We treated two BRAF wild type (MEWO, MJZJ) and two BRAF mutant (A375, A2058) melanoma cell lines with vemurafenib (0.5 lM) and GDC0879 (0.5 lM), and determined the level of PMCA proteins by Western blot analysis (Figs. 1a1 and 1a2 ). Using isoform-specific anti-PMCA antibodies, we identified PMCA1 and PMCA4b (the b splice variant of the PMCA4 proteins) in all cell lines, while PMCA2 and PMCA3 could not be detected in any of the cells tested (Supporting Information Fig. S1a ). Vemurafenib treatment enhanced the level of PMCA4b in the BRAF mutant cell lines substantially whereas the expression of PMCA1 remained constant. Therefore, we focused on PMCA4b in further studies. Semi-quantitative densitometric analysis of the Western blots revealed a 4-to 10-fold increase in the protein level of PMCA4b in the BRAF mutant cells at 0.5 mM vemurafenib concentration (Fig. 1a2, bar graphs) . Figures  1b1 and 1b2 show that changes in the PMCA4b protein level was near maximal at 0.5 mM vemurafenib concentration therefore, we used this vemurafenib concentration in further experiments.
The sarco/endoplasmic reticulum Ca 21 ATPases (SERCAs) also play a major role in maintaining intracellular Ca 21 homeostasis. Accordingly, we examined the changes in SERCA2 and SERCA3 protein levels in vemurafenib treated A375 cells (Fig. 1b1) and found that only SERCA2 was present in this melanoma cell line, and its protein level was not modified by the treatment.
Molecular Cancer Biology
We also tested the effect of vemurafenib treatment on the mRNA expression of PMCA4b in the A375 BRAF mutant cell line (Supporting Information Fig. S1b ) and found that vemurafenib greatly enhanced the mRNA expression of PMCA4b (a time-course is shown in Supporting Information increased in A2058 cells by the treatment while its amount was negligible in A375 cells even after vemurafenib treatment. These results underline the selectivity of PMCA4b upregulation among the Ca 21 signaling molecules in response to BRAF inhibition. MEK1 and MEK2 enzymes lie downstream of BRAF and upstream of ERK1/2 in the Ras/Raf/MEK/ERK signal transduction pathway therefore we treated BRAF mutant melanoma cell lines (A375, A2058) with selumetinib (AZD6244) (0.5 lM), a highly selective MEK1/2 inhibitor. 36 We found that it upregulated PMCA4b to a similar extent as the BRAF selective inhibitor, vemurafenib (Figs. 1c1 and 1c2) . Furthermore, selumetinib treatment enhanced PMCA4b protein level not only in the BRAF mutant cells but also in an NRAS mutant cell line (MJZJ) suggesting that the BRAF/MEK signaling pathway has a key function in the altered protein level of PMCA4b. The relative amount of PMCA4b protein increased 3-5 fold upon selumetinib treatment in both cell types (Fig. 1c2) .
Increased plasma membrane abundance of PMCA4b in vemurafenib-treated BRAF mutant cells is associated with enhanced Ca 21 clearance
Confocal microscopy analysis demonstrated that vemurafenib treatment substantially increased the level of PMCA4b protein in the plasma membrane of BRAF mutant melanoma cells (Fig. 2a) Fig. S2 ). Similar results were obtained when the Ca 21 signal was initiated independently of the Ca 21 entry machinery using the Ca 21 ionophore, A23187 (Fig. 2d1,2,3 ). To further verify the role of PMCA in Ca 21 clearance, we used lanthanum which is a well-known inhibitor of PMCAs. In order to avoid altering the Ca 21 entry pathways we added LaCl 3 immediately after the ionophore induced Ca 21 peak and found that lanthanum strongly inhibited the decay phase of the transient (Fig. 2d1,2) . These results indicate that the up-regulated PMCA4b in BRAF mutant cells was fully functional and it was mostly responsible for the faster Ca 21 clearance after stimulation.
Vemurafenib inhibits the migration of BRAF mutant melanoma cells
Activation of the BRAF/MEK/ERK pathway changes the expression of several proteins involved in the migratory process. 35 ,38 Therefore, we examined the effect of vemurafenib treatment on the migratory activity of a BRAF wild type (MEWO) and two different BRAF mutant melanoma cell lines (A2058, A375) (Fig. 3) . The migration of the cells was recorded by time-lapse video microscopy for 72 hr. Representative trajectories of single cells after 48 hr of vemurafenib treatment clearly show that vemurafenib slows down the migration of the BRAF mutant A375 cell line (Fig. 3a) . The graphs in Figure 3b show that the inhibition of migratory activity of BRAF mutant cells was more pronounced after treating the cells for 48 hr (48-60 hr) while short (0-12 hr) exposure to the drug did not reduce (A2058) or only slightly (A375) decreased cell migration. The rate of inhibition coincided with the vemurafenib-induced increase in PMCA4b abundance that reached saturation at 48-72 hr after exposure to the drug (Supporting Information Fig. S1a) . BRAF wild-type cells (MEWO) migrated much slower than the BRAF mutant cells and their migratory activity did not change in response to vemurafenib treatment, as expected (Fig. 3b) .
PMCA4b overexpression decreases the migratory activity of BRAF mutant A375 cells
The role of store operated Ca 21 entry (SOCE) in melanoma migration has been proposed, but the role of Ca 21 extrusion molecules such as the PMCA has not been addressed in this respect. 15, 16 Since vemurafenib markedly enhanced the abundance of PMCA4b in the plasma membrane and decreased cell migration, we investigated how overexpression of the PMCA4b protein affected melanoma cell motility. To address this we stably transfected MEWO (BRAF wild type) and A375 (BRAF mutant) cell lines with GFP (control) and GFPPMCA4b (Figs. 4a and 4b) . Western blot analysis showed that the newly introduced GFP-PMCA4b protein was expressed in the physiological range both in the two independently generated PMCA4b overexpressing A375 (GFPPMCA4b-I and GFP-PMCA4b-II; Figure 4a , Supporting Information Fig. S3b ) and the BRAF wild-type MEWO cell lines. Confocal imaging demonstrated that the overexpressed pump localized mostly in the plasma membrane (Fig. 4b) . Next we examined whether PMCA4b overexpression affects the proliferation of the BRAF mutant cells using the BrdU Black cell masks were made using ImageJ to emphasize the contour of the cells and display the remarkable change in shape of the PMCA4b-expressing cells. (b2) Area, circularity and aspect of ratio ((major axis)/(minor axis)) parameters of A375 cells expressing GFP (n 5 249) or GFP-PMCA4b (n 5 204) were compared. Bars represent means 6 SEM from three independent experiments. Asterisks (***) denote significant differences compared to cells expressing GFP (p < 0.0001, two-tailed unpaired t-test).
incorporation assay. While 48-hr vemurafenib treatment strongly decreased proliferation, there were no significant differences between control and PMCA4b overexpressing A375 cells (Fig. 4c) . We also showed that the expression levels of BRAF (V600E), pERK and the Ca 21 pump of the internal Ca 21 stores SERCA2 were not altered by PMCA4b overexpression (Fig. 4a, Supporting Information Fig. S3a) .
Next we compared cell motility of A375-GFP and A375-GFP-PMCA4b cell lines and found that PMCA4b strongly decreased the migratory activity of A375 cells (Fig. 5a1,2 and Supporting Information Movies S1 and S2). Similarly to the vemurafenib-treated control cells, GFP-PMCA4b overexpressing A375 cells migrated significantly shorter distances in the given time frame than the untreated GFP-expressing A375 cells (Fig. 5a1,2) .
Changes in motility can be correlated with alterations in cytoskeletal and morphology properties of cells. 39 Remarkably, the reduced migratory activity of GFP-PMCA4b BRAF mutant cells associated with a profoundly altered cell shape. Figure 5b1 shows that the GFP-PMCA4b expressing cells are more round-shaped, with a typical front-to-rear polarity, in contrast to the slender shape of GFP expressing control cells showing more outgrowth that also changes frequently during migration (compare Supporting Information Movies 1 and 2). Significant differences were found among the morphological parameters of the different types of cells; PMCA4b expressing cells showed significantly larger area and circularity, and smaller aspect ratio than control A375 cells (Fig. 5b2,  bar graphs) .
Because of this change in morphology, we analyzed the expression of certain EMT marker proteins, such as Ecadherin, ZEB1, Snail and vimentin 40 by real-time quantitative PCR but no difference in their mRNA expression was found between control and PMCA4b overexpressing A375 cells. Of note, there was no detectable E-cadherin expression in the A375 cells either with or without GFP-PMCA4b (Supporting Information Fig. S3c) .
Altogether, these data demonstrate that overexpression of PMCA4b changes morphology and reduces migratory activity of BRAF mutant A375 cells without having any significant anti-proliferative effect. It is important to note that selective inhibition of BRAF by vemurafenib inhibits both proliferation and migratory activity of these cells.
PMCA4b overexpression decreases the metastatic activity of BRAF mutant A375 cells in vivo
Since migration is a key step in metastasis formation, we compared the metastatic activity of A375-GFP and A375-GFP-PMCA4b cell lines in vivo by performing a lung colonization assay. 6 weeks after tail vein injection, the number of animals with lung metastasis was significantly lower in the groups injected with PMCA4b overexpressing A375 cells as compared with controls (Fig. 6a) . The total area of tumors was dramatically reduced in mice injected with the A375-GFP-PMCA4b cells than in the control group (Fig. 6b) , as representative pictures of cross sections of lungs from A375-GFP-, A375-GFP-PMCA4b-I-and A375-GFP-PMCA4b-IIinjected mice show (Fig. 6c) . Of note, control A375-GFP cells could establish tumors in the lung parenchyma and smaller groups of tumor cells invaded the normal lung tissue along blood vessels or bronchioles in five out of the 8 tumor bearing mice. In contrast, A375-GFP-PMCA4b-I and-II cells formed smaller tumors and their majority was growing on the surface or in the connective tissue compartment of the lungs. Five out of the six tumor-bearing mice injected with A375-GFP-PMCA4b-I or -II cells showed no sign of invasion of the lung parenchyma. This is the first demonstration that PMCA4b has the ability to reduce the metastatic potential of a BRAF mutant melanoma cell line.
In order to demonstrate that PMCA4 expression is related to the malignant progression of melanoma, we analyzed two datasets in the ONCOMINE database 41 where benign nevi and melanoma specimens could be directly compared (Supporting Information Fig. 4) . In both datasets the proportion of cases with high PMCA4 expression was higher in benign nevi than in melanoma cases. 42, 43 Pooling the data from the two cohorts, 21 out of 27 (77%) benign nevi had high PMCA4 expression in contrast to 26 out of 69 (38%) melanomas.
Discussion
In this article, we describe for the first time that a particular variant of the plasma membrane Ca 21 transport ATPase, PMCA4b, regulates cell motility and metastatic capacity of BRAF mutant melanoma cells. We showed that PMCA4b is upregulated upon inhibition of mutant BRAF. Further, we demonstrated that both vemurafenib treatment and PMCA4b overexpression inhibited migration of BRAF mutant cells and the reduced motility of PMCA4b expressing cells was accompanied by a profound change in cell shape. Moreover, we found that overexpression of PMCA4b suppressed metastatic activity of the invasive BRAF mutant A375 cell line. While PMCA4b inhibited motility and metastatic activity of BRAF mutant cells, it did not affect cell growth which by definition is a characteristic of metastasis suppressor genes. 44 It has been suggested that enhanced Ca 21 signaling through store-operated Ca 21 entry can increase cell motility and metastasis. Increased expression of STIM and ORAI proteins caused increased migratory activity of breast cancer, 45 rat aortic vascular smooth muscle 46 and melanoma cells. 15, 16 Inhibition of SOCE by knockdown of STIM and ORAI proteins caused a marked decrease in the migratory and metastatic potential of tumor cells. In good accordance with these findings the down-regulation of cGMP-specific phosphodiesterase PDE5A induced elevated cytosolic Ca 21 levels specifically in BRAF mutant melanomas that resulted in increased contractility and induction of invasion. 47 We may hypothesize that down-regulation of PMCA4b expression also contributes to the elevated cytosolic Ca 21 levels and enhanced cell motility of malignant cells.
In another study high concentration of vemurafenib (6 lM) was shown to induce apoptosis in BRAF mutant melanoma cells by an increase in cytosolic Ca 21 concentration and activation of an ER stress response. 19 In our study, on the other hand, using a much lower (0.5 mM) vemurafenib concentration we demonstrated that in BRAF mutant cells an enhanced PMCA4b expression substantially enhanced cytosolic Ca 21 clearance from the cells and hence decreased cytosolic Ca 21 Our data is in line with other recent observations on endothelial cell migration. It has been shown that PMCA4 localizes mostly at the cell front of migrating human umbilical vein endothelial (HUVEC) cells and that it is essential in maintaining the Ca 21 gradient necessary for directed cell migration. 48 Another group demonstrated that PMCA4 inhibited the motility of VEGF-activated endothelial cells through its inhibitory effect on the calcineurin/NFAT pathway. 49 This is the first time, however, to show that PMCA4b changes shape and motility of a highly aggressive tumor cell line.
Identification of metastasis suppressor genes is of utmost importance since >90% of cancer patients die from metastasis. Our findings suggest that PMCA4b is a major regulator of cell migration and thus of metastatic potential in an exceedingly metastatic malignancy. We found that both mutant BRAF and MEK inhibitor treatment increased PMCA4b abundance in malignant melanoma cells. Furthermore, there were significantly fewer cutaneous melanoma cases with high PMCA4b expression when compared to benign nevi in two gene expression microarray datasets available through the ONCOMINE database. These finding further supports the association of malignant progression with the decrease of PMCA4b expression in melanoma. Downregulation of PMCA4b might be a biomarker for metastatic potential in primary tumors. Our data suggests that it acts as a suppressor and thus agents stimulating its expression or activity rather than inhibitors could have therapeutic benefit. 50 In summary, here we demonstrate for the first time that PMCA4b is a metastatic suppressor protein. We discovered that enhanced PMCA4b abundance induced significant changes in cell shape and motility of a BRAF mutant cell line without affecting proliferation. The pronounced change in cell shape and motility suggest that PMCA4b expression can alter actin polymerization dynamics in highly metastatic cell types and hence inhibit metastasis. Our data support the idea that the enhanced Ca 21 clearance contributes to the antimetastatic function of the pump.
